Parkman Healthcare Partners LLC Sells 46,942 Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Parkman Healthcare Partners LLC reduced its position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 10.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 408,535 shares of the biotechnology company’s stock after selling 46,942 shares during the quarter. Parkman Healthcare Partners LLC owned approximately 0.26% of Ironwood Pharmaceuticals worth $1,810,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also modified their holdings of the company. China Universal Asset Management Co. Ltd. boosted its position in shares of Ironwood Pharmaceuticals by 10.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 33,932 shares of the biotechnology company’s stock worth $150,000 after purchasing an additional 3,209 shares during the period. Swiss National Bank lifted its holdings in shares of Ironwood Pharmaceuticals by 2.2% in the fourth quarter. Swiss National Bank now owns 282,700 shares of the biotechnology company’s stock worth $1,252,000 after buying an additional 6,000 shares in the last quarter. Teacher Retirement System of Texas lifted its holdings in shares of Ironwood Pharmaceuticals by 19.6% in the fourth quarter. Teacher Retirement System of Texas now owns 42,893 shares of the biotechnology company’s stock worth $190,000 after buying an additional 7,020 shares in the last quarter. MetLife Investment Management LLC raised its stake in Ironwood Pharmaceuticals by 10.6% during the fourth quarter. MetLife Investment Management LLC now owns 89,255 shares of the biotechnology company’s stock valued at $395,000 after purchasing an additional 8,559 shares in the last quarter. Finally, Hsbc Holdings PLC lifted its position in Ironwood Pharmaceuticals by 88.9% during the fourth quarter. Hsbc Holdings PLC now owns 20,886 shares of the biotechnology company’s stock valued at $91,000 after purchasing an additional 9,828 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on IRWD shares. JMP Securities lowered their price objective on shares of Ironwood Pharmaceuticals from $23.00 to $14.00 and set a “market outperform” rating for the company in a research report on Thursday, January 30th. StockNews.com upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, May 8th. Wells Fargo & Company reiterated an “equal weight” rating and set a $1.00 price objective (down previously from $7.00) on shares of Ironwood Pharmaceuticals in a research report on Tuesday, April 15th. Leerink Partners lowered their price objective on shares of Ironwood Pharmaceuticals from $3.00 to $1.00 and set a “market perform” rating for the company in a research report on Monday, April 14th. Finally, Craig Hallum lowered shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 16th. Seven research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, Ironwood Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $4.78.

Ironwood Pharmaceuticals Trading Down 6.8%

Ironwood Pharmaceuticals stock opened at $0.68 on Wednesday. The firm has a 50-day moving average price of $1.12 and a 200-day moving average price of $2.61. The firm has a market capitalization of $110.71 million, a PE ratio of -22.81 and a beta of 0.37. Ironwood Pharmaceuticals, Inc. has a 12-month low of $0.59 and a 12-month high of $7.11.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its earnings results on Wednesday, May 7th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.09). The firm had revenue of $41.14 million during the quarter, compared to the consensus estimate of $67.02 million. Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. As a group, sell-side analysts predict that Ironwood Pharmaceuticals, Inc. will post 0.1 earnings per share for the current fiscal year.

Ironwood Pharmaceuticals Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.